Contaminated medicines subjected to urgent recalls (Health Product Recall type I)
| Medications (number of incidents) | Formulation | Defect description |
|---|---|---|
| Marcaine (2), acyclovir (1), nitroglycerin (1), magnesium sulfate (1), dexamethasone sodium (1), vistide (1) and carboplatin (1) | Solution for injection | Visible particulates were identified in the formulation (such as white, metallic or glass particles) |
| Propofol (4) and fat emulsion (1) | Emulsion for injection | |
| Extraneal (1), ciprofloxacin (1), carmustine (1), technetium Tc 99 m (1) and liposomal amphotericin B (1) | Solution for injection | Microbial contamination (bacterial, fungal or viral contamination) |
| Docusate sodium (1) | Capsules | |
| Sucrose (1) | Oral liquid | |
| Benzalkonium chloride (1) | Topical liquid | |
| Sodium chloride (1) and dextrose (1) | Solution for injection | Integrity of the foil seal is compromised leading to potential contamination of the vial adapter |
| Dianeal (1), DTE technetium Tc 99m (1), electrolyte infusion (1) and dextrose (1) | Solution for injection | Lack of sterility assurance at the time of manufacture |
| Gen Teal Artificial Tears (1) | Ophthalmic Solution | |
| Heparin sodium (3) | Solution for injection | Contamination with heparin-like contaminant |
| Quetiapine (3) | Tablets | Cross-contamination of trace amounts of clindamycin in quetiapine active pharmaceutical ingredient during the manufacturing process |
All medicines were reported using Health Product Recall type I document.